Fortress Biotech, Inc. (FBIO) revenue by segment
FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/30
$1.89+0.07 (+3.85%)
Close on Nov 18, 2026Market cap $69.51MP/E –Yield –
Doanh thu theo bộ phận của Fortress Biotech, Inc.
Theo bộ phận kinh doanh
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | $61.86M | $56.13M | $79.18M | – | – | – | – | – | – | – | 97.8% | +10.2% |
| Avenue | $1.40M | – | – | – | – | – | – | – | – | – | 2.2% | – |
| Fortress | – | $1.50M | $5.23M | – | – | – | – | – | – | – | – | – |
| Checkpoint Merger | – | $41.00K | $103.00K | – | – | – | – | – | – | – | – | – |
| Pharmaceutical and Biotechnology Product Development | – | – | $5.33M | $2.07M | $5.66M | $1.07M | $1.71M | $3.51M | $1.73M | $2.57M | – | – |
| Dermatology Products Sales | – | – | $79.18M | $73.67M | $63.13M | $44.53M | $34.92M | $23.38M | $15.52M | $3.59M | – | – |
| Consolidated | – | – | – | – | – | – | – | $26.88M | $17.25M | – | – | – |
| TGTX | – | – | – | – | – | – | – | $3.51M | $1.73M | – | – | – |
| Financial Service Activities | – | – | – | – | – | – | – | – | $170.34M | $10.32M | – | – |
| Lợi nhuận hoạt động | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mustang | -$2.43M | -$16.25M | -$49.26M | – | – | – | – | – | – | – | -85.0% |
| Avenue | -$3.08M | -$11.28M | -$14.54M | – | – | – | – | – | – | – | -72.7% |
| Journey | -$8.17M | -$13.68M | -$2.07M | – | – | – | – | – | – | – | -40.3% |
| Fortress | -$18.50M | -$13.00M | -$24.32M | – | – | – | – | – | – | – | +42.3% |
| Checkpoint Merger | -$38.04M | -$56.17M | -$52.15M | – | – | – | – | – | – | – | -32.3% |
| Pharmaceutical and Biotechnology Product Development | – | – | – | – | – | – | -$106.37M | -$134.63M | -$97.83M | -$59.32M | – |
| Dermatology Products Sales | – | – | – | – | – | – | $4.71M | $3.83M | $312.00K | -$4.45M | – |
| Consolidated | – | – | – | – | – | – | – | -$130.80M | -$97.51M | – | – |
| Financial Service Activities | – | – | – | – | – | – | – | – | -$11.41M | -$1.94M | – |
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qbrexza | $25.01M | $25.11M | $25.41M | $26.72M | $17.06M | $0 | – | – | – | – | 39.5% | -0.4% |
| Emrosi | $14.75M | $0 | – | – | – | – | – | – | – | – | 23.3% | – |
| Accutane | $12.88M | $19.41M | $20.17M | $18.37M | $10.05M | $0 | – | – | – | – | 20.4% | -33.6% |
| Foam franchise products (Amzeeq & Zilxi) | $5.86M | $6.65M | – | – | – | – | – | – | – | – | 9.3% | -11.9% |
| Other / legacy product revenue | $2.74M | $3.96M | $5.92M | – | – | – | – | – | – | – | 4.3% | -30.9% |
| Royalty revenue | $0 | – | – | – | – | – | $100.00K | $400.00K | $1.00M | – | 0.0% | – |
| Zilxi | – | $1.64M | $1.96M | $2.27M | $0 | – | – | – | – | – | – | – |
| Amzeeq | – | $5.01M | $6.20M | $7.24M | $0 | – | – | – | – | – | – | – |
| Collaboration revenue | – | $1.50M | $5.23M | – | – | – | – | – | – | – | – | – |
| Targadox | – | – | $3.20M | $7.97M | $22.38M | $30.71M | $28.07M | $21.23M | $13.75M | – | – | – |
| Ximino | – | – | $287.00K | $4.96M | $8.25M | $9.52M | $3.60M | – | – | – | – | – |
| Exelderm | – | – | $2.40M | $3.46M | $5.36M | $4.45M | – | – | – | – | – | – |
| Luxamend | – | – | $35.00K | $0 | – | – | – | – | – | – | – | – |
| Other Branded Revenue | – | – | – | – | $37.00K | -$148.00K | $6.85M | $2.15M | $1.77M | – | – | – |
| Return Reserve | – | – | – | – | – | – | $2.90M | $2.40M | $1.20M | – | – | – |
| License and Service | – | – | – | – | – | – | $1.70M | $3.50M | – | – | – | – |
Theo khu vực
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Fortress Biotech (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Fortress Biotech, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?